StockData
Travere Therapeutics, Inc. logo

Travere Therapeutics, Inc. (TVTX) stock

TVTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 6/30751% above fair value
$51.10+1.40 (+2.82%)

Close on Nov 17, 2026Market cap $4.82BP/E –Yield –

Travere Therapeutics EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Travere Therapeutics's EV/EBITDA was 201.1× on Nov 11, 2026.

EV/EBITDA at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 2026201.1×–

More Travere Therapeutics figures

See a number that looks wrong?